TBK1 and cancer: In recent years, two TBK1 inhibitors GSK8612 (5)26 and BAY-985 (6),27 reported by GlaxoSmithKline and Bayer, respectively, served as ideal probes to further dissect the biological function of TBK1 in models of immunity and cancer.